R3CE (Rapid, Reproducible, Rare Cell 3D Expansion) is a clinically validated platform capable of generating single cell-derived organoids within one to four weeks. It outperforms currently 3D culture technologies in terms of yields, time to form organoids,easiness of operation. It also demonstrates similar yieldscost structure to 2D culture protocols. R3CE is ready for drug testing for all clinical samplesprovides sufficient quantity of genomic samples derived from cancer patients. It would help conduct clinical cancer treatment in the translational study.
